Ivonescimab is under clinical development by Akeso and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ivonescimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ivonescimab (AK-112) is under development for the treatment of solid tumors like renal cell carcinoma, triple-negative breast cancer, small-cell lung cancer, hepatocellular carcinoma and squamous and non-squamous non-small cell lung cancer, recurrent or metastatic cervical squamous cell carcinoma, endometrial cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma, recurrent or metastatic biliary tract cancers, including intrahepatic cholangiocarcinoma, extrahepatic bile duct cancer, gallbladder cancer, recurrent or metastatic pancreatic ductal adenocarcinoma, esophageal squamous cell carcinoma, transitional cell carcinoma (urothelial cell carcinoma), colorectal cancer, metastatic colorectal cancer, non-small cell lung cancer, small-cell lung cancer, sarcomas and recurrent or metastatic head And neck cancer squamous cell carcinoma, oral cavity (mouth) cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer. The therapeutic candidate is a bi-specific antibody targeting programmed cell death protein 1 (PD-1) and VEGF. It is administered through intravenous and intravenous drip route. It is developed based on antibody analytical platform.
Akeso is a clinical-stage biopharmaceutical company that focus on in-house discovery and development of mono and bi-specific antibody drugs. The company’s product pipeline includes Ak101 and Ak111 targeting plaque psoriasis; Ak102 for treatment of hypercholesterolemia; Ak104 against cancer; Ak105 for treating anlotinib; and Ak112 against solid tumors. It also provides kangfang integrated development platform (ACE Platform) which covers all drug R & D, including target verification, antibody discovery and also development functions. The company works in partnership with MERCK & CO Inc, Dawnrays Pharmaceutical Holdings Ltd, Sino Biopharmaceutical Ltd and China Biopharma. Akeso is headquartered in Zhongshan, Guangdong, China
For a complete picture of Ivonescimab’s drug-specific PTSR and LoA scores, buy the report here.